Wall Street analysts expect Stryker (SYK) to post quarterly earnings of $3.46 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $6.56 billion, up 8.9% from the year-ago quarter.

Over the last 30 days, there has been an upward revision of 0.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

Given this perspective, it's time to examine the average forecasts of specific Stryker metrics that are routinely monitored and predicted by Wall Street analysts.

Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology' reaching $3.59 billion. The estimate indicates a year-over-year change of -4.7%.

Analysts forecast 'Net Sales by Geography- Orthopaedics' to reach $2.96 billion. The estimate indicates a year-over-year change of +31.5%.

The collective assessment of analysts points to an estimated 'Net Sales by Business- MedSurg and Neurotechnology- Medical' of $1.04 billion. The estimate indicates a change of +5.6% from the prior-year quarter.

The combined assessment of analysts suggests that 'Net Sales by Geography- Orthopaedics- Trauma and Extremities' will likely reach $1.05 billion. The estimate points to a change of +9.6% from the year-ago quarter.

The consensus estimate for 'Net Sales by Business- MedSurg and Neurotechnology- Instruments' stands at $1.01 billion. The estimate indicates a year-over-year change of +31.7%.

Based on the collective assessment of analysts, 'Net Sales by Business- MedSurg and Neurotechnology- Endoscopy' should arrive at $946.68 million. The estimate indicates a change of +5.3% from the prior-year quarter.

Analysts predict that the 'Net Sales by Geography- Orthopaedics- Hips' will reach $496.90 million. The estimate points to a change of +6.6% from the year-ago quarter.

The consensus among analysts is that 'Net Sales by Business- MedSurg and Neurotechnology- Vascular' will reach $579.76 million. The estimate indicates a year-over-year change of +16.4%.

Analysts expect 'Net Sales by Geography- Orthopaedics- Knees' to come in at $690.28 million. The estimate points to a change of +7.9% from the year-ago quarter.

It is projected by analysts that the 'Net Sales by Geography- International' will reach $1.65 billion. The estimate indicates a change of +12.5% from the prior-year quarter.

The average prediction of analysts places 'Net Sales by Geography- United States' at $4.90 billion. The estimate suggests a change of +7.6% year over year.

View all Key Company Metrics for Stryker here>>>

Shares of Stryker have demonstrated returns of -0.7% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), SYK is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Stryker Corporation (SYK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research